Sanara MedTech (SMTI) CEO has 491 shares withheld to cover tax on vesting
Rhea-AI Filing Summary
Sanara MedTech Inc.’s Chief Executive Officer, Yon Seth D, reported a Form 4 showing a tax-withholding disposition of 491 shares of common stock on March 1, 2026. These shares were withheld by the company to cover tax obligations from the annual vesting of 1,446 previously granted restricted shares, at a reference price of $20.44 per share. The filing notes that no shares were issued or sold in this transaction, and the CEO’s directly held stake after the withholding was 88,487 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 491 shares
Net Sell
1 txn
Insider
Yon Seth D
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 491 | $20.44 | $10K |
Holdings After Transaction:
Common Stock — 88,487 shares (Direct)
Footnotes (1)
- F1. Represents shares of common stock of Sanara MedTech Inc. (the "Issuer") withheld by the Issuer to satisfy tax withholding obligations in connection with the annual vesting of 1,446 shares of restricted stock previously granted to the reporting person. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Sanara MedTech (SMTI) report for CEO Yon Seth D?
Sanara MedTech reported a tax-withholding disposition by CEO Yon Seth D involving 491 common shares. The shares were withheld by the company to cover tax obligations from vesting restricted stock, rather than sold in the open market.
What triggered the Sanara MedTech (SMTI) tax-withholding disposition reported on Form 4?
The disposition was triggered by the annual vesting of 1,446 restricted shares previously granted to CEO Yon Seth D. To satisfy related tax withholding obligations, Sanara MedTech withheld 491 of those shares instead of the CEO selling shares separately.